**Moderna’s Personalized Cancer Vaccine**

In a **Phase 3** trial, Moderna’s personalized mRNA vaccine intismeran, combined with Merck’s Keytruda, extended recurrence-free and distant metastasis-free survival in **high-risk melanoma patients after surgery**. Moderna shares surged.

The vaccine targets each tumor’s neoantigens. It is the **first successful late-stage trial for an individualized mRNA cancer therapy**.

**** **[@venture](https://t.me/venture)